Hims & Hers is returning to the Super Bowl — one year after its debut spot kicked up a storm of controversy. The telehealth ...

Hims & Hers Health, Inc. (HIMS) ended the recent trading session at $26.44, demonstrating a -2.4% change from the preceding ...

A new take on an old theme: The new Hims ad similarly invokes a system that doesn’t benefit everyone equally but focuses more ...

The ad begins with a family posing for photos while a fast-moving piano riff plays, reminiscent of the title sequence of the ...

"We fully expect this will ruffle some feathers," Hims & Hers chief design officer, Dan Kenger, told Business Insider.

In less than two weeks, more than 120 million people are expected to tune into the biggest advertising moment of the year: the Super Bowl. Companies shelled out about $8 million for 30 seconds of air ...

Advanced cancer detection, hormone therapies and microdoses of GLP-1 sound like medical treatments for the rich and chic. One ...

The telehealth company is back in the fourth quarter of the Big Game, a year after its weight-loss ad drew regulatory and ...

Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market ...

Narrated by Common, Hims & Hers' 2026 Super Bowl ad positions affordability as part of the solution to the income disparities shaping health outcomes.

Hims & Hers Health shows 50% revenue growth, $1B in cash, and 2.4x 2026 sales with strong personalization and GLP-1 sales.

Hims & Hers is a Strong Buy, as shares appear historically cheap due to temporary margin compression and regulatory concerns.